Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Recs

2
Player Avatar whirlyfish (< 20) Submitted: 2/17/2010 11:23:38 AM : Outperform Start Price: $14.79 EBS Score: -27.59

TB and Chlamydia vaccines. As well as upcoming antgrax demand.

Featured Broker Partners


Advertisement